Eton Pharmaceuticals Q4 Revenue Reaches $21.28M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy ETON?
Reports Q4 revenue $21.28M, consensus $20.58M. "It was another phenomenal quarter for Eton with meaningful contributions from key products across our portfolio including INCRELEX, ALKINDI SPRINKLE, KHINDIVI, and GALZIN. The strong fourth quarter helped us cap off a transformational 2025. During the year we launched three major products, INCRELEX, GALZIN, and KHINDIVI, and delivered $80 million in total revenue, more than doubling our 2024 revenue," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ETON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ETON
Wall Street analysts forecast ETON stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.970
Low
26.00
Averages
30.00
High
35.00
Current: 22.970
Low
26.00
Averages
30.00
High
35.00
About ETON
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eton Pharmaceuticals Stock Trend Analysis
- Price Uptrend: Eton Pharmaceuticals has seen a 32.6% price increase over the past 12 weeks, reflecting investors' sustained willingness to pay more for its potential upside, thereby enhancing its appeal for short-term investing.
- Robust Short-Term Performance: The stock has also risen by 24.5% in the last four weeks, further confirming its upward trend and indicating strong market performance in the near term.
- High Trading Signal: Currently, ETON is trading at 94.3% of its 52-week high-low range, suggesting it may be on the verge of a breakout, attracting more investor attention.
- Strong Fundamental Support: Eton holds a Zacks Rank of #1 (Strong Buy), placing it in the top 5% of over 4,000 stocks based on earnings estimate revisions and EPS surprises, indicating strong fundamentals that are expected to drive continued price increases.
See More
Eton Pharma (ETON) Earnings Call Transcript
See More
Eton Pharmaceuticals Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: Eton Pharmaceuticals reported a Q4 non-GAAP EPS of $0.19, missing expectations by $0.01, while revenue reached $21.3 million, reflecting an impressive 82.8% year-over-year growth and exceeding forecasts by $0.72 million, indicating robust market demand and sales performance.
- Future Outlook: The company anticipates revenues will exceed $110 million by 2026, with an adjusted EBITDA margin of at least 30%, suggesting a strong trajectory for profitability and sustained growth in the coming years.
- FDA Approval: Eton received FDA approval for its therapy targeting the rare disorder Desmoda, marking a significant milestone that could enhance the company's competitive edge in niche markets and potentially drive future revenue growth.
- Market Assessment: Eton is viewed as an undervalued small-cap growth stock, with positive market sentiment regarding its future potential, particularly driven by new product launches and strong financial performance, which may attract increased investor interest.
See More
Eton Pharmaceuticals to Announce Q4 Earnings on March 19
- Earnings Announcement Schedule: Eton Pharmaceuticals is set to release its Q4 2023 earnings report after market close on March 19, with a consensus EPS estimate of $0.20, reflecting a remarkable year-over-year growth of 1100%, indicating a significant enhancement in the company's profitability.
- Revenue Growth Expectations: Analysts forecast that Eton's revenue will reach $20.58 million, representing a 76.7% year-over-year increase, suggesting strong sales performance in the market that could attract more investor interest in its growth potential.
- Performance Beat Record: Over the past year, Eton has beaten EPS estimates 50% of the time and has surpassed revenue estimates 100% of the time, reinforcing market confidence in its future financial performance.
- FDA Approval for New Therapy: Eton recently received FDA approval for its Desmoda therapy targeting a rare disorder, further expanding its product line and expected to generate new revenue streams while enhancing its competitive position in the market.
See More
Eton Pharmaceuticals Secures U.S. Rights for Hemangeol Commercialization
- Commercialization Rights Acquisition: Eton Pharmaceuticals announced the acquisition of U.S. commercialization rights for Hemangeol oral solution, indicated for treating proliferating infantile hemangioma, expected to launch on May 1, 2026, which is anticipated to positively impact 2026 earnings.
- Patient Support Program: Eton plans to implement the Eton Cares patient support program, offering prescription fulfillment, insurance benefits investigation, educational support, and financial assistance for qualifying patients, thereby enhancing the company's commitment to social responsibility.
- Market Potential Assessment: Eton estimates that approximately 5,000 to 10,000 infants are treated with Hemangeol annually in the U.S., making it a critical medication as the only systemic therapy, highlighting its strategic significance in the market.
- Product Line Expansion: Eton currently has 10 commercial rare disease products and 4 additional candidates in late-stage development, demonstrating the company's ongoing investment and growth potential in the rare disease sector.
See More
Eton Pharmaceuticals to Report Q4 and Full Year 2025 Financial Results
- Earnings Announcement Schedule: Eton Pharmaceuticals plans to report its Q4 and full year 2025 financial results on March 19, 2026, with management hosting a conference call at 4:30 p.m. ET, which is expected to attract significant investor interest.
- Investor Interaction Opportunity: During the conference call, management will not only answer live questions from participants but also accept emailed inquiries from investors, enhancing trust and transparency in the company's communications.
- Product Line Overview: Eton currently has ten commercial rare disease products, including KHINDIVI™ and INCRELEX®, along with four additional candidates in late-stage development, showcasing the company's ongoing innovation and market potential in the rare disease sector.
- Webcast Access: Investors can access the live webcast on Eton's website, with an archived version available approximately two hours after the event, improving information accessibility for those unable to participate in real-time.
See More
Eton Pharmaceuticals Stock Trend Analysis
- Price Uptrend: Eton Pharmaceuticals has seen a 32.6% price increase over the past 12 weeks, reflecting investors' sustained willingness to pay more for its potential upside, thereby enhancing its appeal for short-term investing.
- Robust Short-Term Performance: The stock has also risen by 24.5% in the last four weeks, further confirming its upward trend and indicating strong market performance in the near term.
- High Trading Signal: Currently, ETON is trading at 94.3% of its 52-week high-low range, suggesting it may be on the verge of a breakout, attracting more investor attention.
- Strong Fundamental Support: Eton holds a Zacks Rank of #1 (Strong Buy), placing it in the top 5% of over 4,000 stocks based on earnings estimate revisions and EPS surprises, indicating strong fundamentals that are expected to drive continued price increases.
See More
Eton Pharma (ETON) Earnings Call Transcript
See More
Eton Pharmaceuticals Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: Eton Pharmaceuticals reported a Q4 non-GAAP EPS of $0.19, missing expectations by $0.01, while revenue reached $21.3 million, reflecting an impressive 82.8% year-over-year growth and exceeding forecasts by $0.72 million, indicating robust market demand and sales performance.
- Future Outlook: The company anticipates revenues will exceed $110 million by 2026, with an adjusted EBITDA margin of at least 30%, suggesting a strong trajectory for profitability and sustained growth in the coming years.
- FDA Approval: Eton received FDA approval for its therapy targeting the rare disorder Desmoda, marking a significant milestone that could enhance the company's competitive edge in niche markets and potentially drive future revenue growth.
- Market Assessment: Eton is viewed as an undervalued small-cap growth stock, with positive market sentiment regarding its future potential, particularly driven by new product launches and strong financial performance, which may attract increased investor interest.
See More
Eton Pharmaceuticals to Announce Q4 Earnings on March 19
- Earnings Announcement Schedule: Eton Pharmaceuticals is set to release its Q4 2023 earnings report after market close on March 19, with a consensus EPS estimate of $0.20, reflecting a remarkable year-over-year growth of 1100%, indicating a significant enhancement in the company's profitability.
- Revenue Growth Expectations: Analysts forecast that Eton's revenue will reach $20.58 million, representing a 76.7% year-over-year increase, suggesting strong sales performance in the market that could attract more investor interest in its growth potential.
- Performance Beat Record: Over the past year, Eton has beaten EPS estimates 50% of the time and has surpassed revenue estimates 100% of the time, reinforcing market confidence in its future financial performance.
- FDA Approval for New Therapy: Eton recently received FDA approval for its Desmoda therapy targeting a rare disorder, further expanding its product line and expected to generate new revenue streams while enhancing its competitive position in the market.
See More
Eton Pharmaceuticals Secures U.S. Rights for Hemangeol Commercialization
- Commercialization Rights Acquisition: Eton Pharmaceuticals announced the acquisition of U.S. commercialization rights for Hemangeol oral solution, indicated for treating proliferating infantile hemangioma, expected to launch on May 1, 2026, which is anticipated to positively impact 2026 earnings.
- Patient Support Program: Eton plans to implement the Eton Cares patient support program, offering prescription fulfillment, insurance benefits investigation, educational support, and financial assistance for qualifying patients, thereby enhancing the company's commitment to social responsibility.
- Market Potential Assessment: Eton estimates that approximately 5,000 to 10,000 infants are treated with Hemangeol annually in the U.S., making it a critical medication as the only systemic therapy, highlighting its strategic significance in the market.
- Product Line Expansion: Eton currently has 10 commercial rare disease products and 4 additional candidates in late-stage development, demonstrating the company's ongoing investment and growth potential in the rare disease sector.
See More
Eton Pharmaceuticals to Report Q4 and Full Year 2025 Financial Results
- Earnings Announcement Schedule: Eton Pharmaceuticals plans to report its Q4 and full year 2025 financial results on March 19, 2026, with management hosting a conference call at 4:30 p.m. ET, which is expected to attract significant investor interest.
- Investor Interaction Opportunity: During the conference call, management will not only answer live questions from participants but also accept emailed inquiries from investors, enhancing trust and transparency in the company's communications.
- Product Line Overview: Eton currently has ten commercial rare disease products, including KHINDIVI™ and INCRELEX®, along with four additional candidates in late-stage development, showcasing the company's ongoing innovation and market potential in the rare disease sector.
- Webcast Access: Investors can access the live webcast on Eton's website, with an archived version available approximately two hours after the event, improving information accessibility for those unable to participate in real-time.
See More
